Insilico Medicine to Present Phase 1 ISM6331 Results at ESMO 2026
Insilico Medicine has announced that first-in-human Phase 1 data for ISM6331, an AI-designed pan-TEAD inhibitor, has been accepted for a ...
Insilico Medicine has announced that first-in-human Phase 1 data for ISM6331, an AI-designed pan-TEAD inhibitor, has been accepted for a ...
Cancer immunotherapy has revolutionized the landscape of blood cancer treatment, especially through the deployment of bioengineered T cells. Among these, ...
In a groundbreaking discovery that may revolutionize the future of cancer immunotherapy, researchers at the UC Davis Comprehensive Cancer Center ...
Success! An email was just sent to confirm your subscription. Please find the email now and click 'Confirm Follow' to start subscribing.
© 2025 Scienmag - Science Magazine
© 2025 Scienmag - Science Magazine